[go: up one dir, main page]

AR079300A1 - Procedimiento de preparacion de un derivado de combretastatina e intermediarios de reaccion - Google Patents

Procedimiento de preparacion de un derivado de combretastatina e intermediarios de reaccion

Info

Publication number
AR079300A1
AR079300A1 ARP100104450A ARP100104450A AR079300A1 AR 079300 A1 AR079300 A1 AR 079300A1 AR P100104450 A ARP100104450 A AR P100104450A AR P100104450 A ARP100104450 A AR P100104450A AR 079300 A1 AR079300 A1 AR 079300A1
Authority
AR
Argentina
Prior art keywords
formula
compound
group
phenyl
derivative
Prior art date
Application number
ARP100104450A
Other languages
English (en)
Inventor
Nicolas Tremaudeux
Pascal Besse
Eric Didier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR079300A1 publication Critical patent/AR079300A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/22Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se refiere a un procedimiento de preparacion de un derivado de combretastatina (1) o (2): que comprende las etapas siguientes: - se hace reaccionar el halogenuro de triaril(3,4,5-trimetoxibencil)fosfonio (3) en la que Ar significa un grupo de arilo elegido entre fenilo o tienilo, con formula (4) o bien formula (5), con el fin de obtener, respectivamente, el compuesto (6) o bien (7): - luego, en el transcurso de una etapa de desproteccion en presencia de un ácido y/o de una base, el compuesto de formula (6) o (7) conduce, después de una etapa eventual de purificacion, al compuesto de formula (1) o (2). Reivindicacion 1: Procedimiento de preparacion de un derivado de combretastatina de formula (1) o (2): Significando A- el anion asociado a un ácido AH, que comprende las etapas siguientes: - se hace reaccionar, en presencia de una base, el halogenuro de triaril(3,4,5- trimetoxibencil)fosfonio (3) en la que Ar significa un grupo de arilo elegido entre fenilo o tienilo, sustituido eventualmente con un grupo de alquilo (C1-4), alcoxi (C1-4) o halogeno, con: - formula (4) en la que R y R' representan: - o cada uno un grupo de alquilo (C1-4); - o bien R representa un grupo de fenilo sustituido eventualmente con un grupo alcoxi (C1-4) y R' representa un átomo de hidrogeno; - o bien R y R' forman conjuntamente con el átomo de carbono al que están unidos un grupo de cicloalquilo (C3-7); - o bien de formula (5) en la que PG1 representa un grupo protector de la funcion alcohol, representando X Boc, Fmoc o CBZ, con el fin de obtener, respectivamente, el compuesto (6) o bien (7): - luego, en el transcurso de una etapa de desproteccion en presencia de un ácido y/o de una base, el compuesto de formula 6 o 7 conduce, después de una etapa eventual de purificacion, al compuesto de formula (1) o (2). Reivindicacion 7: Compuesto de formula (4): en la que R y R' representan: o cada uno un grupo de alquilo (C1-4); o bien R representa un grupo de fenilo sustituido eventualmente con un grupo alcoxi (C1-4) y R' representa un átomo de hidrogeno; o bien R y R' forman conjuntamente con el átomo de carbono al que están unidos un grupo de cicloalquilo (C3-7); y X representa Boc, Fmoc o CBZ. Reivindicacion 10: Compuesto de formula (5): en la que PG1 representa un grupo protector de la funcion alcohol, y X representa Boc, Fmoc o CBZ.
ARP100104450A 2009-12-03 2010-12-02 Procedimiento de preparacion de un derivado de combretastatina e intermediarios de reaccion AR079300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905837A FR2953518B1 (fr) 2009-12-03 2009-12-03 Procede de preparation d'un derive de combretastatine

Publications (1)

Publication Number Publication Date
AR079300A1 true AR079300A1 (es) 2012-01-18

Family

ID=42165674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104450A AR079300A1 (es) 2009-12-03 2010-12-02 Procedimiento de preparacion de un derivado de combretastatina e intermediarios de reaccion

Country Status (17)

Country Link
US (1) US20120302759A1 (es)
EP (1) EP2507218A1 (es)
JP (1) JP2013512883A (es)
KR (1) KR20120104988A (es)
CN (1) CN102906076A (es)
AR (1) AR079300A1 (es)
AU (1) AU2010326423A1 (es)
BR (1) BR112012012908A2 (es)
CA (1) CA2782701A1 (es)
FR (1) FR2953518B1 (es)
IL (1) IL220059A0 (es)
MX (1) MX2012006388A (es)
RU (1) RU2012127575A (es)
SG (1) SG181467A1 (es)
TW (1) TW201127790A (es)
UY (1) UY33080A (es)
WO (1) WO2011067538A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
CN104817519B (zh) * 2015-05-11 2016-11-16 中国药科大学 一类ca-4的衍生物、其制法及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
EP1068870B1 (en) 1998-04-03 2006-06-07 Ajinomoto Co., Inc. Antitumor agents
GB9903403D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
JP4826051B2 (ja) 2000-03-17 2011-11-30 味の素株式会社 スチルベン誘導体の新規結晶及びその製造方法
WO2002006279A1 (en) 2000-07-17 2002-01-24 Oxigene Inc Efficient method of synthesizing combretastatin a-4 prodrugs
JP4779298B2 (ja) 2001-06-25 2011-09-28 味の素株式会社 抗腫瘍剤
US6759555B2 (en) * 2002-04-11 2004-07-06 Aventis Pharma S.A. Process for the preparation of combretastatins
FR2838437B1 (fr) * 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
WO2006042215A1 (en) 2004-10-08 2006-04-20 Janssen Pharmaceutica, N.V. 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
FR2928148B1 (fr) 2008-02-28 2013-01-18 Sanofi Aventis Procede de preparation de combretastatine

Also Published As

Publication number Publication date
IL220059A0 (en) 2012-09-24
RU2012127575A (ru) 2014-01-10
EP2507218A1 (fr) 2012-10-10
SG181467A1 (en) 2012-07-30
AU2010326423A1 (en) 2012-06-21
KR20120104988A (ko) 2012-09-24
CA2782701A1 (fr) 2011-06-09
BR112012012908A2 (pt) 2015-09-08
UY33080A (es) 2011-06-01
TW201127790A (en) 2011-08-16
JP2013512883A (ja) 2013-04-18
CN102906076A (zh) 2013-01-30
WO2011067538A1 (fr) 2011-06-09
MX2012006388A (es) 2012-06-19
FR2953518A1 (fr) 2011-06-10
US20120302759A1 (en) 2012-11-29
FR2953518B1 (fr) 2012-01-20

Similar Documents

Publication Publication Date Title
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
PE20121695A1 (es) 5-alquinil-pirimidinas
HN2011003014A (es) Neocleosidos uracilo espiro ocetano en fecha 16 de noviembre de 2011 se solicita por parte del titular de la invencion modificacion del titulo, ahora se denomina: espironucleosidos uraciclicos oxetanicos
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
AR079055A1 (es) Procedimiento para la preparacion de dabigatran etexilato e intermediarios del mismo
DK1888614T3 (da) Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre
DOP2010000396A (es) Derivado de uracilo o timina para el tratamiento de hepatitis c
CO6220974A2 (es) Derivados de indol 2-carboxamidas y de azaindol 2- carboxamidas sustituidos con un grupo silanilo su preparacion y su aplicacion en terapeutica
AR082937A1 (es) Fosforamidatos de nucleosido
AR082004A1 (es) Compuestos de fusion de piridina
RU2009131835A (ru) Способ получения бетамиметиков
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
AR079300A1 (es) Procedimiento de preparacion de un derivado de combretastatina e intermediarios de reaccion
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
PE20131128A1 (es) Metodo de produccion de un compuestos intermediario para sintetizar un medicamento
JP2016516744A5 (es)
AR071744A1 (es) Proceso para la preparacion de 6-sustituido-1-(2h)-isoquinolinonas, intermediarios para su sintesis y metodos de obtencion de estos intermediarios.
AR060962A1 (es) Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis
AR059613A1 (es) Proceso para la preparacion de compuestos de dibenzotiazepina
AR081720A1 (es) Composicion para el control de plagas
AR072776A1 (es) Procesos para la produccion de 2-amino-2-[2-(4-alquil c2-20-fenil)etil]propano-1,3-dioles y a compuestos intermediarios para usar con los mismos
AR049668A1 (es) Proceso quimico para preparar esteres de 4,4 - difluorometil - 3 - oxo - butanoico por reaccion entre una amida y un ester.
CO6220857A2 (es) Derivados de azabicicloalcano su preparacion y su aplicacion terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure